Overview

Castrate Resistant Prostate Cancer Enhertu Therapy

Status:
RECRUITING
Trial end date:
2028-10-01
Target enrollment:
Participant gender:
Summary
Use of Enhertu as a Subsequent Line of Therapy in HER2-Positive Metastatic Castration-Resistant Prostate Adenocarcinoma.
Phase:
PHASE2
Details
Lead Sponsor:
Washington D.C. Veterans Affairs Medical Center
Collaborators:
Cancer Research And Biostatistics
Daiichi Sankyo
Institute for Clinical Research